Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPARC0912
- Development stage
- Unknown
- Lead developer
- SPARC
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
SPARC0912 is a small molecule drug developed by Sun Pharma Advanced Research Company for the treatment of eye diseases, specifically open-angle glaucoma and ocular hypertension. It has been evaluated in Phase 3 clinical trials as an experimental therapy with a similar active ingredient to Reference0912 but containing a different preservative. The precise mechanism of action for SPARC0912 is not publicly disclosed or remains unknown. As of the latest updates, it has not received regulatory approval in any country and its highest development status is listed as pending[1][2].
- Other names
- Reference0912Reference-0912Reference 0912
Beyond the preview
Go deeper on SPARC0912.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPARC0912.